BD Pays $175M To Resolve Alaris Infusion Pump Financial Fraud Allegations

 
• By Elizabeth Orr

The settlement with the SEC closes out safety issues around the company’s Alaris infusion pumps. BD reportedly failed to alert investors or the FDA of known problems with the infusion pumps’ software for several years.

BD logo on phone screen against financial tracker background.
(Piotr Swat/Shutterstock)

More from Medtech Insight

More from Recalls